1. Home
  2. |Insights
  3. |The Department of Defense Updates Security Requirements for Cloud Services

The Department of Defense Updates Security Requirements for Cloud Services

Client Alert | 1 min read | 02.01.22

The Department of Defense (DoD) recently published Version 1, Release 4 of its Cloud Computing Security Requirements Guide (SRG).  The SRG outlines the administrative, technical, and physical security controls and requirements to be followed by contractors providing cloud services to the DoD pursuant to DFARS 252.239-7010, Cloud Computing Services

The first update in almost five years, Release 4:

  • Reduces the differences between FedRAMP and DoD requirements for cloud services and provides additional guidance with regard to reciprocity between the two authorization regimes;
  • Updates the requirements for cloud services handling personally identifiable and protected health information;
  • Introduces the possibility of higher authorization levels for cloud services offering the DoD physical, rather than logical, separation from other tenants;
  • Clarifies guidance with regard to cloud access points through which a cloud service connects to the DoD’s network; and
  • Makes a number of additional changes to modernize requirements, clarify ambiguities, and reduce redundancy.

The SRG instructs contractors currently providing cloud services to the DoD to transition to the requirements in Release 4 as soon as practical but not later than one year after the SRG’s publication.  Contractors interested in providing cloud services to the DoD should prepare for an assessment against the new requirements, as Release 4 became effective upon publication.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...